{"id":758400,"date":"2023-05-12T07:19:19","date_gmt":"2023-05-12T11:19:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\/"},"modified":"2023-05-12T07:19:19","modified_gmt":"2023-05-12T11:19:19","slug":"plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\/","title":{"rendered":"Plus Therapeutics to Present in EndBrainCancer Initiative Virtual Educational Event"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">AUSTIN, Texas, May  12, 2023  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bHm0dwBM9UjlIjOBBq72Rw1a5ofxCmaII2dnJkC4ORc1L9iSNteZXcEUx731OOQl8OxlXCUgxgGj2Q7ZmGGrE-3tHWv8kSOPWDC_VBgNi5M9ZqNxiW_5w2hGz4fPUKgbPWQ7laUgeR-VPP3ikeTg6MdiPyhGYMnk4b9m-bF4-e3LOtn_eb61tqiiBhuNMIi_tDqdwLVGiC19nTIPWPBVrjyt6nzvDIJavXQr5I-m_sfu8oBcGyCXUIf-rDs5cStOZs-OAp6vfiqmXnVgZWv-jPjlcRdQPS5OlsiPih3KuHCNGNGJ63rxYwC-2S6MMnGkLfpIaSCGdP-k5suUdkp6dcc47VBnYpSRDFYU1sBBLbyITMpd4598VJHx9GysbIcRKvo6ztIq2dnW2DfRo5m4o7lqY5ZZ8dbnaGjfW50yXg4MgeaQDflM3h7tuqq8z6m4dw7RbUubkvBm6D4QBIzdLpWlm5v-pQRLB4UJolW8X3Y=\" rel=\"nofollow noopener\" target=\"_blank\"><u>Plus Therapeutics, Inc.<\/u><\/a> (Nasdaq:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wnoIGMTuyUtRVWyyFCxJG5Nnpdq6nIOX3IBBGmKHfu61pkyEowaFRbHqMcANl1wKjAHuZYMmn-I6d1_YlgxzhpuuViAhkmIIRLIaLmcSOGrZ25rGUIslFu2OzWcCCDBso47WR1R5JNF0XT8mQfHFcQ4F1Gfg9OK_YtDX1FznrMRxZuVKYVbX_jseO_NJFDFp73x3HFXgfAp22lAfo_Saw2BpOAUCY48AfJanj8ZUEkgg_GuYcHhlhhl7ZS-0kU7J_vGQW93gyufVSyX6X785JsFeakmVGEzpYnTa-wJ4rYgKK3XmerZCBz8YPWOIl1JrT7ClRk7deSbpppf87oNkl9LRZTto8uP3OAgPakz5T7nY3pQw-UYe92EZ97d3oM2kAaY6TWJtavMnPrHY3VQeh1GLrMW9RmDTnUGN3b5CDsHsUk9KZYva22k6ALuwBEY4\" rel=\"nofollow noopener\" target=\"_blank\"><u>PSTV<\/u><\/a>) (the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that Norman LaFrance, M.D., Chief Medical Officer and Senior Vice President, will participate in the \u201cKnow All Your Treatment Options 2023\u201d virtual educational event organized by EndBrainCancer Initiative (EBCI).<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <u>Presentation Details <\/u><br \/>\n        <\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:10%;width:10%;min-width:10%;text-align: justify;vertical-align: middle;vertical-align: top\">Topic<\/td>\n<td style=\"max-width:90%;width:90%;min-width:90%;vertical-align: top\">A Novel Targeted Radiotherapeutic for Brain Cancer:\u00a0The ReSPECT Trials<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Date<\/td>\n<td style=\"vertical-align: top\">Friday, May 19, 2023<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Time<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Event begins at 2:00 p.m. ET (11:00 a.m. PT); Dr. LaFrance to present at 3:00 p.m. ET (12:00 p.m. PT)<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Access<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">Registration is free and must be completed by end of day Tuesday, May 16, 2023: <a href=\"https:\/\/lnkd.in\/gArPRzCC\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/lnkd.in\/gArPRzCC<\/a>. The event will be livestreamed on EBCI\u2019s <a href=\"https:\/\/www.facebook.com\/EndBrainCancer\" rel=\"nofollow noopener\" target=\"_blank\">Facebook Page<\/a> at and will be made available on its <a href=\"https:\/\/www.youtube.com\/@ChriselliottfundOrg\" rel=\"nofollow noopener\" target=\"_blank\">YouTube Channel<\/a> two weeks following the event.<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong>About EBCI <\/strong><br \/>\n        <br \/>The EndBrainCancer Initiative | Chris Elliott Fund is dedicated to ensuring that all patients diagnosed with brain cancer, a brain tumor, or metastatic disease to the brain have equal access to advanced diagnostics, FDA-approved treatments, devices, specialists, advanced treatments and clinical trials. We believe that IMMEDIATE ACCESS to these options provides the patient community with the best HOPE for survival and sustained quality of life. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vI6MLgevNmI9sgj5RyLKXlbNLFzLuLXV1i0NahUBC3xnxNReak7UPkm93Zl0KUTfBfEcu7Cnp1aRYIflAabu_h4HfHX4HZeFgkVItwwJTCc=\" rel=\"nofollow noopener\" target=\"_blank\">www.EndBrainCancer.org<\/a><\/p>\n<p align=\"justify\">\n        <strong>About Plus Therapeutics<\/strong><br \/>\n        <br \/>Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a robust supply chain through strategic partnerships that enable the development, manufacturing and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cwDDA_ggnDCLXU9OWZJOGsde6HXhYW-LkrN3Iv_WPBXVdfFE5PvbpYyiawIqlhE92ZS-8hds_SKB2-ghi9p_gKfTypySdQJZpTHj29wHa0Q=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/plustherapeutics.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Cautionary Statement Regarding Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains statements that may be deemed \u201cforward-looking statements\u201d within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as \u201cdesigned to,\u201d \u201cwill,\u201d \u201ccan,\u201d \u201cpotential,\u201d \u201cfocus,\u201d \u201cpreparing,\u201d \u201cnext steps,\u201d \u201cpossibly,\u201d and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of <sup>186<\/sup>Re including the ability of <sup>186<\/sup>Re to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company\u2019s future performance including the next steps in developing the Company\u2019s current assets; the Company\u2019s clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM and ReSPECT-LM clinical trials; possible negative effects of <sup>186<\/sup>Re; the continued evaluation of <sup>186<\/sup>Re including through evaluations in additional patient cohorts; and the intended functions of the Company\u2019s platform and expected benefits from such functions.<\/p>\n<p align=\"justify\">The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company\u2019s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company\u2019s product candidates and therapies, the results of the Company\u2019s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company\u2019s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company\u2019s partnering\/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, among others; and additional risks described under the heading \u201cRisk Factors\u201d in the Company\u2019s Securities and Exchange Commission filings, including in the Company\u2019s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.<\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Peter Vozzo<br \/>ICR Westwicke<br \/>(443) 377-4767<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MXPeWUPBtcoDXYuJCRujPlO6pvdvPBT2-iBKGNcQ9cc8onQVL0AO6pDPPoqg4xpXLUzmHQ_iaaJZF-N2AfbJueAKiCp17_Xm-U9OsvHm3no=\" rel=\"nofollow noopener\" target=\"_blank\">Peter.Vozzo@westwicke.com<\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Terri Clevenger<br \/>ICR Westwicke<br \/>(203) 856-4326<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5rJ4UEPvmgd7bythdG2nDInSf1pbZfRh9W0U252EseNDd5CCkgx5T2hMnxvme1BjCGaMAHUeRE9vFGgXukNGoDbRk_1o5bHuCTgqQHUvzqHZloUq1wWUeESCJEP9Et-u\" rel=\"nofollow noopener\" target=\"_blank\">Terri.Clevenger@westwicke.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzkzOSM1NTkxNTE1IzIwMDQ4MDU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MDkxNTFkNWQtY2I0OS00ZmUzLWIxNTEtZWFkZjk3NDkxNmU1LTEwMTYzNzg=\/tiny\/Plus-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AUSTIN, Texas, May 12, 2023 (GLOBE NEWSWIRE) &#8212; Plus Therapeutics, Inc. (Nasdaq:\u00a0PSTV) (the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that Norman LaFrance, M.D., Chief Medical Officer and Senior Vice President, will participate in the \u201cKnow All Your Treatment Options 2023\u201d virtual educational event organized by EndBrainCancer Initiative (EBCI). Presentation Details Topic A Novel Targeted Radiotherapeutic for Brain Cancer:\u00a0The ReSPECT Trials Date Friday, May 19, 2023 Time Event begins at 2:00 p.m. ET (11:00 a.m. PT); Dr. LaFrance to present at 3:00 p.m. ET (12:00 p.m. PT) Access Registration is free and must be completed by end of day Tuesday, May 16, 2023: https:\/\/lnkd.in\/gArPRzCC. The event will be &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Plus Therapeutics to Present in EndBrainCancer Initiative Virtual Educational Event&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-758400","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Plus Therapeutics to Present in EndBrainCancer Initiative Virtual Educational Event - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Plus Therapeutics to Present in EndBrainCancer Initiative Virtual Educational Event - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AUSTIN, Texas, May 12, 2023 (GLOBE NEWSWIRE) &#8212; Plus Therapeutics, Inc. (Nasdaq:\u00a0PSTV) (the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that Norman LaFrance, M.D., Chief Medical Officer and Senior Vice President, will participate in the \u201cKnow All Your Treatment Options 2023\u201d virtual educational event organized by EndBrainCancer Initiative (EBCI). Presentation Details Topic A Novel Targeted Radiotherapeutic for Brain Cancer:\u00a0The ReSPECT Trials Date Friday, May 19, 2023 Time Event begins at 2:00 p.m. ET (11:00 a.m. PT); Dr. LaFrance to present at 3:00 p.m. ET (12:00 p.m. PT) Access Registration is free and must be completed by end of day Tuesday, May 16, 2023: https:\/\/lnkd.in\/gArPRzCC. The event will be &hellip; Continue reading &quot;Plus Therapeutics to Present in EndBrainCancer Initiative Virtual Educational Event&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-12T11:19:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzkzOSM1NTkxNTE1IzIwMDQ4MDU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Plus Therapeutics to Present in EndBrainCancer Initiative Virtual Educational Event\",\"datePublished\":\"2023-05-12T11:19:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\\\/\"},\"wordCount\":824,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNzkzOSM1NTkxNTE1IzIwMDQ4MDU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\\\/\",\"name\":\"Plus Therapeutics to Present in EndBrainCancer Initiative Virtual Educational Event - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNzkzOSM1NTkxNTE1IzIwMDQ4MDU=\",\"datePublished\":\"2023-05-12T11:19:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNzkzOSM1NTkxNTE1IzIwMDQ4MDU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNzkzOSM1NTkxNTE1IzIwMDQ4MDU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Plus Therapeutics to Present in EndBrainCancer Initiative Virtual Educational Event\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Plus Therapeutics to Present in EndBrainCancer Initiative Virtual Educational Event - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\/","og_locale":"en_US","og_type":"article","og_title":"Plus Therapeutics to Present in EndBrainCancer Initiative Virtual Educational Event - Market Newsdesk","og_description":"AUSTIN, Texas, May 12, 2023 (GLOBE NEWSWIRE) &#8212; Plus Therapeutics, Inc. (Nasdaq:\u00a0PSTV) (the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that Norman LaFrance, M.D., Chief Medical Officer and Senior Vice President, will participate in the \u201cKnow All Your Treatment Options 2023\u201d virtual educational event organized by EndBrainCancer Initiative (EBCI). Presentation Details Topic A Novel Targeted Radiotherapeutic for Brain Cancer:\u00a0The ReSPECT Trials Date Friday, May 19, 2023 Time Event begins at 2:00 p.m. ET (11:00 a.m. PT); Dr. LaFrance to present at 3:00 p.m. ET (12:00 p.m. PT) Access Registration is free and must be completed by end of day Tuesday, May 16, 2023: https:\/\/lnkd.in\/gArPRzCC. The event will be &hellip; Continue reading \"Plus Therapeutics to Present in EndBrainCancer Initiative Virtual Educational Event\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-12T11:19:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzkzOSM1NTkxNTE1IzIwMDQ4MDU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Plus Therapeutics to Present in EndBrainCancer Initiative Virtual Educational Event","datePublished":"2023-05-12T11:19:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\/"},"wordCount":824,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzkzOSM1NTkxNTE1IzIwMDQ4MDU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\/","name":"Plus Therapeutics to Present in EndBrainCancer Initiative Virtual Educational Event - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzkzOSM1NTkxNTE1IzIwMDQ4MDU=","datePublished":"2023-05-12T11:19:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzkzOSM1NTkxNTE1IzIwMDQ4MDU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzkzOSM1NTkxNTE1IzIwMDQ4MDU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-therapeutics-to-present-in-endbraincancer-initiative-virtual-educational-event\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Plus Therapeutics to Present in EndBrainCancer Initiative Virtual Educational Event"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/758400","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=758400"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/758400\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=758400"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=758400"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=758400"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}